Ribosomal Protection Proteins and Their Mechanism ofTetracyclineResistance
Top Cited Papers
- 1 December 2003
- journal article
- review article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (12), 3675-3681
- https://doi.org/10.1128/aac.47.12.3675-3681.2003
Abstract
Objective To determine whether autologous infusions of expanded regulatory T lymphoctyes (Tregs) into patients with amyotrophic lateral sclerosis (ALS) are safe and tolerable during early and later stages of disease. Methods Three patients with ALS, with no family history of ALS, were selected based on their differing sites of disease onset and rates of progression. Patients underwent leukapheresis, and Tregs were subsequently isolated and expanded ex vivo. Tregs (1 × 106 cells/kg) were administered IV at early stages (4 doses over 2 months) and later stages (4 doses over 4 months) of disease. Concomitant interleukin-2 (2 × 105 IU/m2/injection) was administered subcutaneously 3 times weekly over the entire study period. Patients were closely monitored for adverse effects and changes in disease progression rates. Treg numbers and suppressive function were assayed during and following each round of Treg infusions. Results Infusions of Tregs were safe and well tolerated in all patients. Treg numbers and suppressive function increased after each infusion. The infusions slowed progression rates during early and later stages of disease. Spearman correlation analyses showed that increased Treg suppressive function correlated with slowing of disease progression per the Appel ALS scale for each patient: patient 1: ρ (rho) = −0.60, p = 0.003; patient 2: ρ = −0.71, p = 0.0026; and patient 3: ρ = −0.54, p = 0.016. Measures of maximal inspiratory pressure also stabilized, particularly in 2 patients, during Treg infusions. Conclusions These results demonstrate the safety and potential benefit of expanded autologous Treg infusions, warranting further clinical trials in patients with ALS. The correlation between Treg suppressive function and disease progression underscores the significance of using Treg suppressive function as an indicator of clinical status. Classification of evidence This study provides Class IV evidence. This is a phase I trial with no controls.Keywords
This publication has 60 references indexed in Scilit:
- Initiation Factor IF2, Thiostrepton and Micrococcin Prevent the Binding of Elongation Factor G to the Escherichia coli RibosomeJournal of Molecular Biology, 2002
- Classification and evolution of P-loop GTPases and related ATPasesJournal of Molecular Biology, 2002
- The Complete Atomic Structure of the Large Ribosomal Subunit at 2.4 Å ResolutionScience, 2000
- Role of Domains 4 and 5 in Elongation Factor G Functions on the RibosomeJournal of Molecular Biology, 2000
- VMD: Visual molecular dynamicsJournal of Molecular Graphics, 1996
- Tet(O), a protein that mediates ribosomal protection to tetracycline, binds, and hydrolyses GTPCanadian Journal of Microbiology, 1995
- Characterization of an oxytetracycline‐resistance gene, otrA, of Streptomyces rimosusMolecular Microbiology, 1991
- Colicin E3 induced cleavage of 16S ribosomal ribonucleic acid. Blocking effects of certain antibioticsBiochemistry, 1973
- Role of magnesium in the binding of tetracycline to Escherichia coli ribosomesJournal of Molecular Biology, 1971
- Inhibition of aminoacyl-sRNA binding to ribosomes by tetracyclineBiochemical and Biophysical Research Communications, 1965